Bank of New York Mellon Corp boosted its stake in Hill-Rom Holdings Inc (NYSE:HRC) by 53.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,235,608 shares of the medical technology company’s stock after buying an additional 427,888 shares during the period. Bank of New York Mellon Corp owned about 1.88% of Hill-Rom Holdings worth $98,367,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of HRC. Independent Portfolio Consultants Inc. raised its stake in shares of Hill-Rom Holdings by 171.5% in the second quarter. Independent Portfolio Consultants Inc. now owns 1,344 shares of the medical technology company’s stock valued at $107,000 after buying an additional 849 shares during the period. Meadow Creek Investment Management LLC raised its stake in shares of Hill-Rom Holdings by 3.9% in the first quarter. Meadow Creek Investment Management LLC now owns 1,696 shares of the medical technology company’s stock valued at $120,000 after buying an additional 64 shares during the period. Neuburgh Advisers LLC raised its stake in shares of Hill-Rom Holdings by 3.9% in the first quarter. Neuburgh Advisers LLC now owns 2,332 shares of the medical technology company’s stock valued at $165,000 after buying an additional 88 shares during the period. Tyers Asset Management LLC raised its stake in shares of Hill-Rom Holdings by 3.9% in the first quarter. Tyers Asset Management LLC now owns 2,968 shares of the medical technology company’s stock valued at $210,000 after buying an additional 112 shares during the period. Finally, Bancorpsouth Inc. purchased a new stake in shares of Hill-Rom Holdings during the first quarter valued at about $210,000. 84.27% of the stock is owned by hedge funds and other institutional investors.

Shares of Hill-Rom Holdings Inc (NYSE:HRC) opened at 74.29 on Friday. The stock has a 50 day moving average price of $77.92 and a 200-day moving average price of $73.80. The company has a market cap of $4.89 billion, a price-to-earnings ratio of 43.29 and a beta of 1.22. Hill-Rom Holdings Inc has a 1-year low of $50.50 and a 1-year high of $84.65.

Hill-Rom Holdings (NYSE:HRC) last announced its quarterly earnings data on Friday, July 28th. The medical technology company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.01. Hill-Rom Holdings had a net margin of 4.27% and a return on equity of 19.99%. The company had revenue of $689.10 million during the quarter, compared to analysts’ expectations of $695.50 million. During the same quarter in the prior year, the company earned $0.81 EPS. Hill-Rom Holdings’s revenue was up 5.1% compared to the same quarter last year. Equities research analysts forecast that Hill-Rom Holdings Inc will post $3.82 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 15th will be paid a dividend of $0.18 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.72 annualized dividend and a yield of 0.97%. Hill-Rom Holdings’s dividend payout ratio is presently 41.62%.

COPYRIGHT VIOLATION NOTICE: “Hill-Rom Holdings Inc (HRC) Shares Bought by Bank of New York Mellon Corp” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/26/hill-rom-holdings-inc-hrc-shares-bought-by-bank-of-new-york-mellon-corp.html.

Several brokerages have issued reports on HRC. Cantor Fitzgerald set a $86.00 price target on Hill-Rom Holdings and gave the stock a “hold” rating in a research note on Friday, July 28th. Zacks Investment Research lowered Hill-Rom Holdings from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. BidaskClub lowered Hill-Rom Holdings from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Morgan Stanley lifted their price target on Hill-Rom Holdings from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, June 30th. Finally, Needham & Company LLC dropped their price target on Hill-Rom Holdings from $95.00 to $93.00 and set a “buy” rating for the company in a research note on Friday, July 28th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $88.17.

In related news, SVP Andreas G. Frank sold 10,660 shares of the company’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $78.62, for a total transaction of $838,089.20. Following the completion of the sale, the senior vice president now owns 28,988 shares of the company’s stock, valued at approximately $2,279,036.56. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 2.20% of the stock is currently owned by corporate insiders.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Institutional Ownership by Quarter for Hill-Rom Holdings (NYSE:HRC)

Receive News & Stock Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related stocks with our FREE daily email newsletter.